What is LIBTAYO 350 mg and what is it used for
LIBTAYO 350 mg is an anticancer medicine that contains the active substance cemiplimab, which is a monoclonal antibody.
Libtayo (cemiplimab) is a medicine used to treat advanced cutaneous squamous cell carcinoma (CCCC), advanced basal cell carcinoma (BCC), and advanced non-small cell lung cancer (NSCLC).
LIBTAYO is used in adults to treat:
- A type of skin cancer called advanced cutaneous squamous cell carcinoma (SCCC)
- A type of skin cancer called advanced basal cell carcinoma (BC) for which you have been treated with a Hedgehog signaling pathway inhibitor and this treatment did not work well or was not well tolerated.
- A type of lung cancer called non-small cell lung carcinoma (NSCLC).
- A type of cancer called cervical cancer that has gotten worse during or after chemotherapy.
LIBTAYO 350 mg can be given in combination with chemotherapy for NSCLC. It is important that you also read the leaflets for the specific chemotherapy you may be receiving. If you have any questions about these medicines, ask your doctor.
LIBTAYO 350 mg works by helping your immune system fight cancer.
How to use LIBTAYO
- You will be given LIBTAYO in a hospital or clinic – supervised by a doctor experienced in treating cancer.
- LIBTAYO is given into a vein by drip (intravenous infusion).
- The infusion will last about 30 minutes.
- LIBTAYO is usually given every 3 weeks.
Package contents and other information
The active substance is cemiplimab:
- One ml of concentrate contains 50 mg cemiplimab.
- Each vial contains 350 mg cemiplimab in 7 ml of concentrate.
The other ingredients are L-Histidine, L-Histidine monohydrochloride monohydrate, L-proline, sucrose, polysorbate 80 and water for injections.
